Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
6
×
boston top stories
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
6
×
detroit blog main
detroit top stories
immunotherapy
6
×
indiana blog main
indiana top stories
life sciences
national
6
×
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
6
×
wisconsin top stories
merck
cancer
pfizer
celgene
fda
medicare
nivolumab
novartis
roche
abbvie
acquisition
What
annual
bio
roundup
cancer
celgene
clinical
conference
drug
esmo
european
medical
new
oncology
price
society
advantages
airport
apocalypse
approval
ash
bar
barcelona
beds
biogen’s
biopharma
biopharmaceutical
breast
brings
cancer's
car
colleagues
companies
convo
data
days
december's
earlier
exome
expect
failures
Language
unset
Current search:
immunotherapy
×
national
×
" wisconsin blog main "
×
" boston blog main "
×
" bristol-myers squibb "
×
@xconomy.com
4 years ago
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More
@xconomy.com
5 years ago
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More
@xconomy.com
5 years ago
ESMO ’18: Precision Meds, Breast, Lung, and More from the Cancer Front